Search

everythinglearnresearchcommunity

for

Search:↓

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

Genetic testing for cancer risk can lead to early and life-saving treatments in people without symptoms.

Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.

ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.

Spironolactone does not increase cancer risk and may lower prostate cancer risk, but more research is needed.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Melatonin affects many body functions beyond sleep by interacting with specific receptors in various tissues.

Hormone therapy affects cancer risks in transgender individuals differently than in cisgender people, and more research is needed to understand these risks and improve cancer screening guidelines.

Women with PCOS have a higher risk of diabetes, heart problems, certain cancers, and mental health issues, but early treatment can help manage these risks.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

No definitive link between finasteride and male breast cancer, but further research is needed.

PCOS may increase the risk of certain cancers.

Testosterone therapy seems safe and effective for transgender men with proper care, but more long-term research is needed.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

The number of advanced breast cancer cases in women under 40 has increased, but the overall numbers are still low.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.

Hair dyes and perms can damage hair and scalp, but using interventions can reduce harm.

Human hair shows promise for non-invasive medical testing, but more research is needed to standardize its use.

Women with PCOS have higher risks of heart disease, type 2 diabetes, and endometrial cancer.

Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.

Connexin-26 gene mutations may increase cancer risk in KID syndrome patients.

Transplant patients on immunosuppressive medications have a higher risk of skin cancer, and managing this involves balancing medication with cancer risk.

Finasteride treats hair loss and reduces prostate cancer risk.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

The paper concludes that breast cancer treatment involves complex interactions between medical symptoms, patient experiences, and commercial influences, requiring a holistic approach.